5 Facts You May Not Want to Know About Medicare in 2026

Medicare beneficiaries face higher out-of-pocket costs in 2026 as Part A inpatient deductibles rise (inpatient deductible to $1,736 from $1,676; daily coinsurance for days 61–90 to $434; lifetime reserve day coinsurance to $868; SNF days 21–100 to $217) and a minority without sufficient work credits will pay a $565 Part A premium (up $47). Part B standard monthly premiums jump to $202.90 (from $185) and the Part B deductible to $283 (from $257), with 20% coinsurance continuing to apply to services; significant coverage gaps remain for dental, vision, hearing and long-term care. These changes increase retiree healthcare cost exposure, likely boosting demand for Medigap/Medicare Advantage/Part D products and affecting consumer spending among retirees and provider reimbursement dynamics, while limited provider participation and a modest physician opt-out (about 1% of non‑pediatric physicians in 2024) could constrain access in some markets.

Analysis

Market structure: Incremental but persistent Medicare cost shifts favor payers and managed-care intermediaries (UNH, HUM, CI, CVS, CNC) that can reprice risk and cap out-of-pocket exposure. Providers with high Medicare/Medicaid mixes (UHS, HCA, SNF operators, senior-housing REITs like WELL) face margin pressure and potential volume loss as beneficiaries delay elective care; expect a 100–300bps margin tailwind for large MA-specialists versus a similar compression for exposed providers over 12–24 months.

Risk assessment: Tail risks include a sudden CMS policy shift (drug-price negotiation expansion or >3% unexpected cuts to MA benchmarks), physician opt-out clusters in rural markets, or litigation that forces wider networks—each could swing margins ±10–20% for plans/providers. Immediate catalysts: Oct–Dec 2025 AEP enrollment and mid-2026 CMS rate notices; material regime shifts would show up in 3–9 months, secular demographic tailwinds persist 5–10 years.

Trade implications: Favor long, selective insurer/MA exposure and selective short bets on providers/REITs and SNF operators. Use options to lever conviction (9–15 month calls on UNH/HUM) and protective collars for hospitals; allocate tactically ahead of AEP (enter by Oct 1, 2025) and re-evaluate after CMS rate publication within 30 days.

Contrarian angles: The market underestimates upside to MA enrollment from rising Part B/Part A costs — insurers may widen spread vs private plans; conversely, senior-housing pessimism may be overdone if Medicaid conversion stabilizes occupancy. Watch for unintended policy backlash against narrow networks that could compress insurer spreads, a 6–12 month execution risk.

Key Decisions for Investors

• Establish a 2–3% long position in UnitedHealth (UNH) and a 1–2% long in Humana (HUM) and Centene (CNC) by Oct 1, 2025 to capture Medicare Advantage enrollment tailwinds; trim if quarterly MA membership growth falls below +5% YoY or company-reported MA margin falls >200bps versus guidance.
• Initiate a 1.0–1.5% short exposure to senior-housing REITs (e.g., WELL) and select provider operators with >40% Medicare/Medicaid revenue (e.g., UHS) using equity or 6–12 month put spreads; cut losses if occupancy recovers above 90% or Medicaid revenue share declines >5ppt within two quarters.
• Buy 9–15 month call options (10–15% OTM) on UNH and HUM representing 0.5–1% of portfolio capital to leverage upside from MA pricing; hedge by buying 6–9 month protective puts on a hospital provider ETF or UHS (size 0.5% capital) to cap downside from policy shocks.
• Monitor three actionable triggers over the next 30–180 days: (1) CMS draft MA rate memo (if cuts >3% vs consensus, reduce longs within 7 days); (2) Oct–Dec 2025 AEP enrollment data (if MA net gains <2% QoQ, reweight toward cash); (3) bipartisan legislative drug-price headlines (if expansion appears likely, increase hedges on pharma exposure and favor insurers by +1% allocation).